Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

Jakob Grauslund, D.M.Sci., PhD, MD, from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Trump has not withdrawn his threats against Denmark on Greenland. This is what Danish PM Mette Frederiksen said during a confidential meeting of the Foreign Policy Committee with the leader of Venstre ...

President-elect Trump's threat to tariff Denmark if it resists his acquisition ... giant Novo Nordisk is the sole owner of semaglutide, the active ingredient in both Ozempic and Wegovy.

Semaglutide, the active ingredient in Ozempic and Wegovy, is primarily manufactured in Denmark, although Novo Nordisk has some manufacturing capacity in Clayton, North Carolina. It's likely ...

makes the main active ingredient - semaglutide - in its popular obesity and diabetes injections Wegovy and Ozempic in Denmark, and exports it to the United States. In the first nine months of 2024 ...